SpO

₂

≥94%

No hospitalization is necessary

Molnupiravir used orally twice daily 800 mg for 5

days⁸

Kasirivimab / imdevimab used intravenously or subcutaneously as a single dose of 1200 mg

(600/600 mg)⁹

Inhaled budesonide at a dose of 2 × 800 μg

daily¹

Antipyretic drugs (paracetamol, ibuprofen, etc)

Rest

Oral hydration

Low‑molecular‑weight heparin in patients who are chronically bedridden only

Antitussive drugs for persistent cough

Systemic corticosteroids are contraindicated.

Antibiotics and anti‑influenza medications are contraindicated, unless there is a coinfection with bacterial infection or concomitant influenza.

Oxygen saturation control using the Pulsocare remote alarm system (using pulse oximeters)

SpO

₂

<⁠94%

Usually week 1 after disease onset

Hospitalization is required

Remdesivir intravenously administered once daily for 5 days, loading dose on day 1: 200 mg, then maintenance dose: 100 mg for 4 days. Contraindicated in patients with: eGFR <⁠30 ml / min/1.73 m

²

; ALT activity ≥5 times the upper limit of

normal¹⁰

Molnupiravir administered orally twice daily 800 mg for 5

days⁸

Kasirivimab / imdevimab administered intravenously or subcutaneously in a single dose of 1200 mg

(600/600 mg)⁹

Low‑molecular‑weight heparin in prophylactic or therapeutic doses

Dexamethasone can be considered, but only in patients receiving antiviral drugs and oxygen therapy, orally or intravenously 4–8 mg/d; should not be used in the first week of the disease if antiviral drugs are not used.

Antibiotic therapy in the case of secondary bacterial infections

Symptomatic treatment

Oxygen therapy

Oral or intravenous hydration

SpO

₂

<⁠90%

Usually week 2 after disease onset

Hospitalization is required

Tocilizumab (in people with IL‑6 concentration >100 pg/ml) in a single intravenous infusion of 800 mg if BW >90 kg; 600 mg if BW 65–90 kg; 400 mg if BW 40–65 kg and 8 mg/kg if BW ≤40 kg. In case of no improvement, the second dose may be repeated after 8–24 hours. Contraindicated in patients with: absolute neutrophil count <⁠2000/µl; active

tuberculosis.¹¹

Baricitinib orally 4 mg a day until the end of hospitalization, but not longer than 14 days; recommended especially in patients requiring high‑flow oxygen therapy. There is no evidence of benefit with tocilizumab. Contraindicated in patients with: eGFR <⁠30 ml/min/1.73 m

²

, dose reduced to 2 mg daily in patients with eGFR 30–60 ml/min/1.73 m

²

and >75 years of age; risk of thrombosis and embolism; active

tuberculosis.¹²

Dexamethasone phosphate administered intravenously in a daily dose of 6–8 mg

^c

for 7–10 days

Low‑molecular‑weight heparin in prophylactic or therapeutic doses

Antibiotic therapy in the case of secondary bacterial infections

Symptomatic treatment

Low- / high‑flow oxygen therapy

Intravenous hydration

Unsuccessful pharmacotherapy to date

Need for mechanical ventilation

ICU treatment is required

Dexamethasone phosphate administered intravenously in a daily dose of 6–8 mg

^c

for 7–10 days. If dexamethasone is not available, other corticosteroids may be given at equivalent doses, eg: hydrocortisone, 3 × 50 mg intravenously; methylprednisolone 4 × 10 mg intravenously; prednisone 1 × 40 mg orally

Tocilizumab in combination with dexamethasone can be administered to patients who require mechanical lung ventilation. It should be administered as soon as possible, in the first 24 hours of ventilation. Contraindicated in patients with: absolute neutrophil count <⁠2000/µl; active

tuberculosis.¹¹

High‑flow oxygen therapy

Noninvasive ventilation

Invasive ventilation

Extracorporeal veno‑venous transmembrane oxygenation (VV ECMO) in selected patients

Low‑molecular‑weight heparin in prophylactic or therapeutic doses depending on the clinical situation

Empiric antibiotic therapy is strongly discouraged unless there is evidence of a bacterial infection.